Denmark-based non-invasive human diagnostics company, RSP Systems has received grant to support the market launch of its non-invasive glucose monitor, GlucoBeam.
The €2.4m grant is a part of European Union's Horizon 2020 framework for research and innovation.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
RSP Systems CEO Dr Anders Weber said: "This vital grant will help to overcome the biggest issue in glucose monitoring: compliance.
"For patients to finally be able to measure their glucose levels using the non-invasive GlucoBeam will be a real breath of fresh air.
"With the completion of a commercial product aided by Horizon 2020, we can now identify the best path to the best partners to make GlucoBeam broadly available to patients in the European and later global markets."
Based on RSP's proprietary and clinically validated technology, critical depth raman spectroscopy, GlucoBeam is used for glucose measurement in living tissue.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt is easy to use and is compliant with the recommended glucose monitoring schemes since the usage of the device causes no pain and inconvenience.
The device is wirelessly integrated with a smartphone/tablet app to store and analyse the glucose data which can be shared with physicians.
GlucoBeam is designed to support integration to cloud based Internet Blood Glucose Monitoring services. Sharing of the glucose data enables physicians to optimise their treatment while minimising chances of complications.
